Weight-Loss Jabs Don't Work the Same for Everyone
Genetic variations in gut hormone pathways explain why GLP-1 treatments produce wildly different results.
Scientists analyzed data from almost 28,000 patients taking GLP-1 medications like Ozempic and Wegovy. The Guardian reports that variations in two genes controlling gut hormone pathways—which regulate appetite and digestion—directly impact how well these weight-loss treatments work. Some people lose significant weight while others see minimal results or experience severe side effects, all based on their genetic makeup.
This follows the exact trajectory of personalized medicine moving from theory to mainstream practice. For the past decade, the assumption was that blockbuster drugs work uniformly across populations. That assumption has collapsed. First came personalized cancer treatments based on tumor genetics. Then pharmacogenomics testing for antidepressants. Now genetic screening is reaching the obesity market, worth $200 billion globally. The one-size-fits-all era of medicine is ending, replaced by treatments as unique as fingerprints.
When biology becomes data, every body becomes a unique optimization problem requiring personalized solutions.
Build genetic testing into treatment protocols before prescribing expensive GLP-1 medications. Personalized medicine is shifting from premium add-on to standard care, creating massive opportunities for diagnostic companies and data platforms.
Source: The Guardian